4.7 Article

Translational research on u-PAR

Journal

EUROPEAN JOURNAL OF CANCER
Volume 46, Issue 7, Pages 1241-1251

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2010.02.029

Keywords

u-PAR

Categories

Funding

  1. Alfried Krupp von Bohlen und Halbach Foundation, Essen
  2. Hella-Buhler-Foundation, Heidelberg
  3. Dr. Ingrid zu Solms Foundation, Frankfurt/Main
  4. Hector Foundation, Weinheim, Germany
  5. FRONTIER Excellence Initiative of the University of Heidelberg
  6. Walter Schulz Foundation, Munich, Germany

Ask authors/readers for more resources

The urokinase receptor (u-PAR) is one of the most critical molecules in migration, invasion, intravasation, and metastasis and is also a key regulator between tumour cell proliferation and dormancy. It is overexpressed in most human solid cancer types, which has led to increasing translational and clinical research on this molecule. The current review discusses in particular the in vivo, translational, and putative clinical relevance of u-PAR in the context of this latest development. It outlines how u-PAR is already being used and might increasingly be applied as a diagnostic tool, for example, in distinguishing benign from malignant neoplasms, as a molecular marker for predicting clinical response to chemotherapy or novel targeted therapy, and finally as a promising tool for the development of novel cancer therapeutics. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available